Powerful beneficial effects of macrophage colony-stimulating factor on -amyloid deposition and cognitive impairment in Alzheimers disease

Alzheimers disease is a major cause of dementia in humans. The appearance of cognitive decline is linked to the overproduction of a short peptide called -amyloid (A) in both soluble and aggregate forms. Here, we show that injecting macrophage colony-stimulating factor (M-CSF) to Swedish -amyloid precursor protein (APP(Swe))/PS1 transgenic mice, a well-documented model for Alzheimers disease, on a weekly basis prior to the appearance of learning and memory deficits prevented cognitive loss. M-CSF also increased the number of microglia in the parenchyma and decreased the number of A deposits. Senile plaques were smaller and less dense in the brain of M-CSF-treated mice compared to littermate controls treated with vehicle solution. Interestingly, a higher ratio of microglia internalized A in the brain of M-CSF-treated animals and the phagocytosed peptides were located in the late endosomes and lysosomes. Less A(40) and A(42) monomers were also detected in the extracellular protein enriched fractions of M-CSF-treated transgenic mice when compared with vehicle controls. Finally, treating APP(Swe)/PS1 mice that were already demonstrating installed A pathology stabilized the cognitive decline. Together these results provide compelling evidence that systemic M-CSF administration is a powerful treatment to stimulate bone marrow-derived microglia, degrade A and prevent or improve the cognitive decline associated with A burden in a mouse model of Alzheimers disease.